Use este identificador para citar ou linkar para este item:
http://hdl.handle.net/1843/61860| Tipo: | Artigo de Periódico |
| Título: | Cost-effectiveness of anti-SARS-CoV-2 antibody diagnostic tests in Brazil |
| Autor(es): | Tália Santana Machado de Assis Mariana Lourenço Freire Janaína de Pina Carvalho Ana Rabello Glaucia Fernandes Cota |
| Resumo: | Background Although serologic tests for COVID-19 diagnosis are rarely indicated nowadays, they remain commercially available and widely used in Brazil. The objective of this study was to evaluate the cost-effectiveness of anti-SARS-CoV-2antibody diagnostic tests for COVID-19 in Brazil. Methods Eleven commercially available diagnostic tests, comprising five lateral-flow immunochromatographic assays (LFAs) and six immunoenzymatic assays (ELISA) were analyzed from the perspective of the Brazilian Unified Health System. Results The direct costs of LFAs ranged from US$ 11.42 to US$ 17.41and of ELISAs, from US$ 6.59 to US$ 10.31. Considering an estimated disease prevalence between 5% and 10%, the anti-SARS-CoV-2 ELISA (IgG) was the most cost-effective test, followed by the rapid One Step COVID-19 Test, at an incremental cost-effectiveness ratio of US$ 2.52 and US$ 1.26 per properly diagnosed case, respectively. Considering only the LFAs, at the same prevalence estimates, two tests, the COVID-19 IgG/IgM and the One Step COVID-19 Test, showed high effectiveness at similar costs. For situations where the estimated probability of disease is 50%, the LFAs are more costly and less effective alternatives. Conclusions Nowadays there are few indications for the use of serologic tests in the diagnosis of COVID-19 and numerous commercially available tests, with marked differences are observed among them. In general, LFA tests are more cost-effective for estimated low-COVID-19- prevalences, while ELISAs are more cost-effective for high-pretest-probability scenarios. |
| Assunto: | Teste para COVID-19 Avaliação de Custo-Efetividade Brasil |
| Idioma: | eng |
| País: | Brasil |
| Editor: | Universidade Federal de Minas Gerais |
| Sigla da Instituição: | UFMG |
| Departamento: | HCL - HOSPITAL DAS CLINICAS MEDICINA - FACULDADE DE MEDICINA |
| Tipo de Acesso: | Acesso Aberto |
| Identificador DOI: | https://doi.org/10.1371/journal.pone.0264159 |
| URI: | http://hdl.handle.net/1843/61860 |
| Data do documento: | 25-Fev-2022 |
| metadata.dc.url.externa: | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0264159 |
| metadata.dc.relation.ispartof: | Plos One |
| Aparece nas coleções: | Artigo de Periódico |
Arquivos associados a este item:
| Arquivo | Descrição | Tamanho | Formato | |
|---|---|---|---|---|
| Cost-effectiveness of anti-SARS-CoV-2 antibody diagnostic tests in Brazil.pdf | 231.05 kB | Adobe PDF | Visualizar/Abrir |
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.